Drug development for children: How adequate is the current European ethical guidance?

Archives of Disease in Childhood

Volumn 95, Issue 1, 2010, Pages 3-6

  Westra, A E ^a   Engberts, D P ^a   Sukhai, R N ^a   Wit, J M ^a   De Beaufort, I D ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; CHILD HEALTH; CLINICAL PROTOCOL; DRUG RESEARCH; EUROPE; HUMAN; HUMAN RIGHTS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESEARCH ETHICS; REVIEW; RISK ASSESSMENT; ARTICLE; DRUG APPROVAL; DRUG DEVELOPMENT; ETHICS; EUROPEAN UNION; PEDIATRICS;

CHILD; DRUG APPROVAL; DRUG DISCOVERY; ETHICS, RESEARCH; EUROPEAN UNION; HUMANS; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC;

EID: 75349104483     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.135103     Document Type: Review

References (18)

1. European Union. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, OJ No L378/1, 27 December 2006. http://ec.europa.eu.enterprise/pharmaceuticals/eudralex/vol1/reg-2006- 1901/reg-2006-1901-en.pdf. (accessed 1 April 2009).
2. Council of Europe. Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: convention on human rights and biomedicine. Paris: Council of Europe,1997. http://conventions.coe.int/Treaty/EN/Treaties/Html/164.htm (accessed 25 Mar 2009).
3. European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Eur J Health Law 2008;15:223-50.
4. Burger D. De dupe van beschermende regels. Verruim de voorwaarden voor fase-1-onderzoek met kinderen [The victim of protection-based regulations: extend the possibilities for phase 1 research with children]. (In Dutch.) Med Contact 2007;62:1248-50.
5. Council of Europe. Additional protocol to the convention on human rights and biomedicine, concerning biomedical research. Paris: Council of Europe, 2005. http://conventions.coe.int/treaty/en/Treaties/Html/195.htm (accessed 25 Mar 2009).
6. Greig JM, Ellis CJ, Smith EG. Septic discitis and other complications of peripheral venous cannulation. QJM 2002;95:412-3.
7. Soifer NE, Borzak S, Edlin BR, et al. Prevention of peripheral venous catheter complications with an intravenous therapy team: a randomized controlled trial. Arch Intern Med 1998;158:473-7.
8. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48.
9. Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007;21:F1-10.
10. Janofsky J, Starfield B. Assessment of risk in research on children. J Pediatr 1981;98:842-6.
11. Shah S, Whittle A, Wilfond B, et al. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA 2004;291:476-82.
12. Wendler D. Protecting subjects who cannot give consent: toward a better standard for "minimal" risks. Hastings Cent Rep 2005;35:37-43.
13. Resnik DB. Eliminating the daily life risks standard from the definition of minimal risk. J Med Ethics 2005;31:35-8.
14. Kopelman LM. Minimal risk as an international ethical standard in research. J Med Philos 2004;29:351-78.
15. Nelson RM, Ross LF. In defense of a single standard of research risk for all children. J Pediatr 2005;147:565-6.
16. Fisher CB, Kornetsky SZ, Prentice ED. Determining risk in pediatric research with no prospect of direct benefit: time for a national consensus on the interpretation of federal regulations. Am J Bioeth 2007;7:5-10.
17. Kopelman LM. Moral problems in assessing research risk. IRB 2000;22:3-6.
18. US Department of Health and Human Services. Protection of human subjects. 45 CFR 146. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm (Revised 23 June 2005; effective 23 June 2005) (accessed 25 Mar 2009).